Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Wei D Ding"'
Autor:
Michael J. Johnson, Sameer A. Parikh, Paul J. Hampel, Timothy G. Call, Jose F. Leis, Jennifer Canniff, Wei D Ding, Congrong Miao, Jennifer A Whitaker, Matthew A. Holets, Richard B. Kennedy, Kari G. Rabe, Neil E. Kay, Heather C. Darby, Eli Muchtar, Myron J. Levin, Saad S. Kenderian, D. Scott Schmid, Yucai Wang, Adriana Weinberg, Amber B. Koehler, Susan L. Slager, Suzanne R. Hayman
Publikováno v:
Am J Hematol
Monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B cell disorders associated with increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd7c7c96af526974f3410155b41ff533
https://doi.org/10.1002/ajh.26388
https://doi.org/10.1002/ajh.26388
Autor:
Timothy G. Call, Neil E. Kay, Sameer A. Parikh, Luis F. Porrata, Susan M. Schwager, Wei D Ding, Thomas M. Habermann, William R. Macon, Jose F. Leis, Kay M. Ristow, Susan L. Slager, Tait D. Shanafelt, Kari G. Chaffee
Publikováno v:
American Journal of Hematology. 90:334-338
Although transformation to Hodgkin lymphoma (HL) is a recognized complication in patients with chronic lymphocytic leukemia (CLL), its incidence, clinical characteristics and outcomes are not well defined. We used the Mayo Clinic CLL and Lymphoma Dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3d7a18d3fa2087365b6b649ea83a262
https://doi.org/10.1002/ajh.23939
https://doi.org/10.1002/ajh.23939
Autor:
Rhett P. Ketterling, Nanna H. Sulai, Shahrukh K. Hashmi, Wei D Ding, Thomas E. Witzig, Mrinal M. Patnaik, William J. Hogan, Timothy G. Call, Moussab Damlaj, Jennifer L. Oliveira, Mark R. Litzow, Grzegorz S. Nowakowski, Tait D. Shanafelt
Publikováno v:
Clinical lymphoma, myelomaleukemia. 15(11)
We conducted a single-center retrospective analysis to determine the impact of the anti-CD52 monoclonal antibody alemtuzumab including route of administration compared to non-alemtuzumab-containing regimens in T-prolymphocytic leukemia (T-PLL).The st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0f9e3bdd7b2970e371b072a79732e6
https://pubmed.ncbi.nlm.nih.gov/26422251
https://pubmed.ncbi.nlm.nih.gov/26422251